Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roth Trades Stop-Loss For 80/20 Split: Appears Unattractive To Drug Industry

Executive Summary

Finance Committee Chairman Roth's initial approach to catastrophic coverage in a Medicare drug benefit differs substantially from the other major proposals pending on Capitol Hill.

You may also be interested in...



PhRMA/BIO Get "Innovation" And "Modern Medicare" Into GOP Rhetoric

Sen. Frist (R-Tenn.) spotlighted "innovation" as the updated GOP theme for protecting the drug industry against anticipated attacks from the Gore campaign during an Aug. 3 speech to the Republican National Convention in Philadelphia.

PhRMA/BIO Get "Innovation" And "Modern Medicare" Into GOP Rhetoric

Sen. Frist (R-Tenn.) spotlighted "innovation" as the updated GOP theme for protecting the drug industry against anticipated attacks from the Gore campaign during an Aug. 3 speech to the Republican National Convention in Philadelphia.

Medicare Rx Mark-Up By Senate Finance Delayed Until After Recess

The Senate Finance Committee will not mark up Medicare reform legislation that would establish a prescription drug benefit until after the August congressional recess.

Related Content

UsernamePublicRestriction

Register

PS036358

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel